Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Intervention: Subcutaneous Lenacapavir Clear all

Conditions: HIV Infections
Interventions: Cabotegravir long-acting, Lenacapavir long-acting; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Long Beach, California

Conditions: HIV-1-infection
Interventions: Oral Lenacapavir, F/TAF, Subcutaneous Lenacapavir, TAF, BIC, B/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 49
States / cities: Phoenix, Arizona • Los Angeles, California • Palm Springs, California + 40 more

Conditions: HIV-1 Infection
Interventions: Oral Lenacapavir, Subcutaneous Lenacapavir, Teropavimab, Zinlirvimab; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 23
States / cities: Los Angeles, California • Sacramento, California • San Diego, California + 19 more

Conditions: Pre-Exposure Prophylaxis of HIV Infection
Interventions: Lenacapavir Tablet, Lenacapavir Injection, Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 253 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 11
States / cities: Birmingham, Alabama • San Diego, California • Washington D.C., District of Columbia + 7 more

Conditions: HIV Infections
Interventions: Lenacapavir, Lenacapavir Tablet, Teropavimab, Zinlirvimab, Cabotegravir, Rilpivirine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 16
States / cities: San Francisco, California • DeLand, Florida • Fort Lauderdale, Florida + 12 more

Conditions: Human Immunodeficiency Virus
Interventions: Lenacapavir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV-1 Infection
Interventions: Teropavimab, Zinlirvimab, Lenacapavir Tablet, Lenacapavir Injection, Antiretroviral Therapy; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 29
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 25 more

Conditions: HIV-1-infection
Interventions: Lenacapavir, Lenacapavir Tablet, Teropavimab, Zinlirvimab, SBR; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 2
States / cities: Berkeley, Michigan • Annandale, Virginia

Conditions: HIV-1-infection
Interventions: Oral Lenacapavir, Oral Lenacapavir Placebo, Subcutaneous Lenacapavir, Failing ARV Regimen, Optimized Background Regimen (OBR); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 12 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 35
States / cities: Los Angeles, California • Palm Springs, California • Sacramento, California + 28 more

Conditions: Pre-Exposure Prophylaxis of HIV Infection
Interventions: Oral Lenacapavir (LEN), F/TDF, Sub-cutaneous (SC) Lenacapavir (LEN), Placebo SC LEN, PTM F/TDF, PTM Oral LEN, F/TAF (for US participants only); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 16 Years and older
Enrollment: 3,292 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 60
States / cities: Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 43 more

Conditions: HIV-1-infection
Interventions: Oral Lenacapavir, Subcutaneous Lenacapavir, Optimized Background Regimen (OBR); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: Up to 17 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Pre-Exposure Prophylaxis of HIV Infection
Interventions: Lenacapavir Injection, Lenacapavir Tablet, Emtricitabine/tenofovir disoproxil fumarate (F/TDF); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 181 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 9
States / cities: Los Angeles, California • San Diego, California • Miami, Florida + 6 more

Conditions: HIV Infections
Interventions: Lenacapavir Injection, Emtricitabine/tenofovir disoproxil fumarate (F/TDF), Emtricitabine/tenofovir alafenamide (F/TAF), Cabotegravir (CAB), Lenacapavir Tablet; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Timeline: 2026 – 2029
U.S. locations: 34
States / cities: Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 23 more

Search by objective public record fields.

A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIV

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV

Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)

Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy

A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance

Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection

Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)

Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention